Cas No.Product NameDescription
220127-57-1Imatinib mesylateImatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia .
796967-16-3LinifanibLinifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
790299-79-5MasitinibMasitinib also known as Masivet, AB1010 is a tyrosine kinase, c-Kit, PDGFR, FGFR3, the FAK pathway inhibitor with IC50 of 150 ± 80, 200 ± 40 nM.
850879-09-3AmuvatinibMP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Met, c-Kit, PDGFRalpha, Flt3, and c-Ret and with an IC50 of median 5 μM.
943319-70-8PonatinibPonatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.
728033-96-3OSI-930OSI-930 is an inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).
1174046-72-0BMS-794833BMS 794833 is a potent ATP competitive inhibitor of Met (IC50 = 1.7 nM) and Flk-1 (IC50 = 15 nM).
940310-85-0NVP-BHG712NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively.
219580-11-7PD173074PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, FGFR1 and VEGFR2, respectively.
875337-44-3MGCD-265MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases.
811803-05-1ApatinibApatinib (YN968D1) is a novel, orally bioavailable, selective inhibitor with potential antiangiogenic and antineoplastic activities.
288383-20-0 CediranibCediranib is VEGFR2 inhibitor. Cediranib inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50s of 0.4 and 0.5 nM, respectively.
152459-95-5ImatinibImatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
656247-17-5IntedanibBIBF-1120 (Vargatef) is an inhibitor of VEGFR, PDGFR and FGFR.
284461-73-0Sorafenib Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
341031-54-7Sunitinib MalateSunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
649735-46-6BrivanibBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
649735-63-7Brivanib alaninateBrivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM.
417716-92-8LenvatinibLenvatinib is inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM)
443913-73-3VandetanibVandetanib is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway